ArticleJournal of medical virology2025
Japanese Encephalitis Virus Genotype 5 Infectious Clone and Reporter System for Antiviral Evaluation.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reverse Genetics of Orthoflaviviruses: Strategies for Constructing Functional or Infectious cDNA.Journal of medical virology · 2026Review
- Advances and Challenges in Vaccination and Therapeutic Strategies Against Japanese Encephalitis Virus.Pathogens (Basel, Switzerland) · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The recent emergence of Japanese encephalitis virus genotype 5 (JEV5) has raised concerns regarding limited vaccine efficacy. Here, we report the construction of a full-length infectious cDNA clone of JEV5 using a bacterial artificial chromosome (BAC) system, based on a South Korea isolate, K15P38 strain. The resulting clone enabled recovery of replication-competent virus and was genetically distinguishable from the parental strain via engineered silent mutations. To extend its application, we introduced nanoluciferase and enhanced green fluorescent protein into the viral genome, generating reporter viruses suitable for replication tracking. Both reporter viruses supported real-time quantification of viral replication and demonstrated utility in antiviral compound screening. Antiviral evaluation using the nucleoside analog NITD008 yielded EC₅₀ values consistent between reporter and classical plaque assays. These findings provide a reverse genetics platform for studying JEV5 and suggest applicability for genotype-specific vaccine and antiviral research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.